IOVA Quote, Financials, Valuation and Earnings

Lantheus Holdings, Inc. has a net margin of -135.28% compared to Iovance Biotherapeutics, Inc.'s net margin of 7.23%. Iovance Biotherapeutics, Inc.'s return on equity of -54.43% beat Lantheus Holdings, Inc.'s return on equity of 14.66%.

Iovance Biotherapeutics, Inc. has a consensus price target of $7.75, signalling upside risk potential of 213.77%. On the other hand Lantheus Holdings, Inc. has an analysts' consensus of $81.43 which suggests that it could grow by 53.61%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Lantheus Holdings, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Lantheus Holdings, Inc..

Iovance Biotherapeutics, Inc. has a beta of 0.869, which suggesting that the stock is 13.15% less volatile than S&P 500. In comparison Lantheus Holdings, Inc. has a beta of 0.040, suggesting its less volatile than the S&P 500 by 95.995%.

Iovance Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lantheus Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics, Inc. pays -- of its earnings as a dividend. Lantheus Holdings, Inc. pays out -- of its earnings as a dividend.

Iovance Biotherapeutics, Inc. quarterly revenues are $67.5M, which are smaller than Lantheus Holdings, Inc. quarterly revenues of $384M. Iovance Biotherapeutics, Inc.'s net income of -$91.3M is lower than Lantheus Holdings, Inc.'s net income of $27.8M. Notably, Iovance Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Lantheus Holdings, Inc.'s PE ratio is 22.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics, Inc. is 3.27x versus 2.42x for Lantheus Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Microbot Medical, Inc. has a net margin of -135.28% compared to Iovance Biotherapeutics, Inc.'s net margin of --. Iovance Biotherapeutics, Inc.'s return on equity of -54.43% beat Microbot Medical, Inc.'s return on equity of -45.11%.

Iovance Biotherapeutics, Inc. has a consensus price target of $7.75, signalling upside risk potential of 213.77%. On the other hand Microbot Medical, Inc. has an analysts' consensus of $12.00 which suggests that it could grow by 479.71%. Given that Microbot Medical, Inc. has higher upside potential than Iovance Biotherapeutics, Inc., analysts believe Microbot Medical, Inc. is more attractive than Iovance Biotherapeutics, Inc..

Iovance Biotherapeutics, Inc. has a beta of 0.869, which suggesting that the stock is 13.15% less volatile than S&P 500. In comparison Microbot Medical, Inc. has a beta of 1.217, suggesting its more volatile than the S&P 500 by 21.732%.

Iovance Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Microbot Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics, Inc. pays -- of its earnings as a dividend. Microbot Medical, Inc. pays out -- of its earnings as a dividend.

Iovance Biotherapeutics, Inc. quarterly revenues are $67.5M, which are larger than Microbot Medical, Inc. quarterly revenues of --. Iovance Biotherapeutics, Inc.'s net income of -$91.3M is lower than Microbot Medical, Inc.'s net income of -$3.6M. Notably, Iovance Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Microbot Medical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics, Inc. is 3.27x versus -- for Microbot Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -135.28% compared to Iovance Biotherapeutics, Inc.'s net margin of -316.61%. Iovance Biotherapeutics, Inc.'s return on equity of -54.43% beat Plus Therapeutics, Inc.'s return on equity of --.

Iovance Biotherapeutics, Inc. has a consensus price target of $7.75, signalling upside risk potential of 213.77%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $9.67 which suggests that it could grow by 1415.15%. Given that Plus Therapeutics, Inc. has higher upside potential than Iovance Biotherapeutics, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Iovance Biotherapeutics, Inc..

Iovance Biotherapeutics, Inc. has a beta of 0.869, which suggesting that the stock is 13.15% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.773, suggesting its less volatile than the S&P 500 by 22.731%.

Iovance Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Iovance Biotherapeutics, Inc. quarterly revenues are $67.5M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Iovance Biotherapeutics, Inc.'s net income of -$91.3M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Iovance Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics, Inc. is 3.27x versus 8.20x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Talphera, Inc. has a net margin of -135.28% compared to Iovance Biotherapeutics, Inc.'s net margin of -9603.7%. Iovance Biotherapeutics, Inc.'s return on equity of -54.43% beat Talphera, Inc.'s return on equity of -133.55%.

Iovance Biotherapeutics, Inc. has a consensus price target of $7.75, signalling upside risk potential of 213.77%. On the other hand Talphera, Inc. has an analysts' consensus of $3.25 which suggests that it could grow by 160%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Talphera, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Talphera, Inc..

Iovance Biotherapeutics, Inc. has a beta of 0.869, which suggesting that the stock is 13.15% less volatile than S&P 500. In comparison Talphera, Inc. has a beta of 0.151, suggesting its less volatile than the S&P 500 by 84.887%.

Iovance Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Talphera, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics, Inc. pays -- of its earnings as a dividend. Talphera, Inc. pays out -- of its earnings as a dividend.

Iovance Biotherapeutics, Inc. quarterly revenues are $67.5M, which are larger than Talphera, Inc. quarterly revenues of $1K. Iovance Biotherapeutics, Inc.'s net income of -$91.3M is lower than Talphera, Inc.'s net income of -$4.4M. Notably, Iovance Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Talphera, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics, Inc. is 3.27x versus 1,434.04x for Talphera, Inc.. Usually stocks with elevated PS ratios are considered overvalued.